The prediction of prognosis in patients with early breast cancer is an issue of paramount importance, not only in hormone receptor-positive/HER2-negative disease, where prognostication may settle whether adjuvant chemotherapy should be administered or not, but also in HER2-positive disease. This evidence concerns the gene NR4A1 and breast cancer.